Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Switzerland’s Poor Performance In 2010 Heralds Uncertain Future For The Industry

Executive Summary

The Swiss pharmaceutical industry is seizing upon the deficit that hit the country's drug sector in 2010 – the first in nearly 50 years – to launch a campaign against policies instigated by the Swiss Federal Office of Public Health (BAG).

You may also be interested in...

Swiss Agreement Sees Drug Prices Fall But Access Accelerated

The Swiss government and the pharmaceutical industry have reached an agreement that will see prices slashed by 20% over the next three years, but reimbursement decisions to be accelerated by over 300%.

EU Drug Pricing: The Only Way Is Down

Pricing pressure in Europe is hardly new, but it became a much bigger concern in 2010. The last 18 months have seen some of the most severe and certainly the most numerous, price cuts across the region. Although individual European countries represent only a small share of Big Pharma revenues, the EU as a whole is the world's second-largest market in sales terms, only slightly smaller than the U.S.

Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs

For the generic drug industry, 2011 is just about utopia, while for brand drug makers it marks the end of an era. With Pfizer's blockbuster statin Lipitor (atorvastatin) – the world's top-selling drug with more than $11 billion in sales – expected to go generic in the U.S. in November, it marks a symbolic shift from the blockbuster primary care glory days of the late 1990s to the highly genericized, highly fragmented market of today.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts